Sensyne Health PLC Agreement with NHS Greater Glasgow and Clyde (8455A)
01 October 2020 - 11:00PM
UK Regulatory
TIDMSENS
RNS Number : 8455A
Sensyne Health PLC
01 October 2020
Sensyne Health and NHS Greater Glasgow and Clyde sign data
access agreement
Oxford, U.K. 1 October 2020: Sensyne Health plc (LSE: SENS)
("Sensyne" or the "Company" or the "Group"), the UK Clinical AI
company, today announces it has signed a non-exclusive data sharing
agreement with NHS Greater Glasgow and Clyde ("NHSGGC") giving
Sensyne access to three separate anonymised patient data sets in
three specific disease areas including cardiovascular disease.
The anonymised patient data will be used by Sensyne to undertake
medical research using Clinical AI, improve pharmaceutical
development and help deliver better patient care.
NHSGGC is one of 14 regional NHS Boards in Scotland. It serves a
population of 1.14 million and employs around 39,000 staff. It is
the largest NHS organisation in Scotland and one of the largest in
the UK including 35 Hospitals of different types.
The agreement falls under the Glasgow Safe Haven partnership
between NHS Greater Glasgow and Clyde and the University of
Glasgow, designed to provide secure access to NHS and other health
datasets derived from diverse sources across the health service.
The Glasgow Safe Haven is accredited by the Scottish Government as
an accredited Safe Haven, and is one of four regional Safe Havens
across Scotland. By enabling researchers to link data from
different sources, Safe Havens encourage data-driven health
research to improve health services, design better treatments, and
to create innovative new health products to support better health
in Scotland.
Prof Julie Brittenden, Director of Research and Innovation, NHS
Greater Glasgow and Clyde, said:
"We are pleased to collaborate with Sensyne on data-driven
approaches which aim to ultimately improve early diagnosis and
treatment of various illnesses, including cardiovascular disease.
The project will use anonymised patient data within the secure
Glasgow Safehaven to test Sensyne's machine learning models. This
is one of many of our collaborations with industry to improve
research and development in order to benefit our patients in
future."
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
"We are delighted to be working with one of the largest NHS
Boards in Scotland on data analysis to improve patient care and
accelerate medical research. Adding this data sharing agreement to
our Strategic Research Agreements expands our access to anonymised
patient data to now cover 3.9 million patients."
-ENDS-
For more information please contact:
Sensyne Health ( www.sensynehealth.com +44 (0) 330 058
) 1845
Lord (Paul) Drayson PhD FREng, Chief Executive
Officer
Michael Norris, Interim Chief Financial
Officer
Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418
Broker) 8900
Dr Christopher Golden
James Steel
Oliver Jackson
+ 44 (0) 20 3100
Liberum (Joint Broker) 2000
Bidhi Bhoma
Euan Brown
+44 (0) 77 0286
Consilium Strategic Communications 8207
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
CSCS ensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in
partnership with the NHS to improve patient care and accelerate the
discovery and development of new medicines. Sensyne Health is
listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRFSAFEFESSEIS
(END) Dow Jones Newswires
October 01, 2020 09:00 ET (13:00 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From May 2023 to May 2024